Conference Roundup
Infectious Diseases

Candida Auris and Risk of Bloodstream Infections

Posted on February 26, 2020
Candida Auris and Risk of Bloodstream Infections

Candida auris infection is still rare in the United States but several states have reported continuing outbreaks of this emerging multidrug-resistant fungus, including New York State. During ID Week 2018, NY researchers shared their 2-year experience with this fungal infection, which can progress to bloodstream infections (BSI).

Between September 2016 and March 2018, 187 cases of C auris were identified across New York State. Assessment of data for these patients revealed the following:

  • Seven patients (4%) progressed to BSI during at least 24,781 days of follow-up (median, 98 patient days; range, 0-548 days), indicating a BSI rate of 0.3 per 1000 patient days.
  • Median time from date of first colonization to date of BSI was 86 days (range, 3-310 days).
  • All patients developing BSI had portals of entry, such as indwelling catheters or chronic wounds.
  • Neurologic diseases and diabetes were associated with an increased risk of BSI.

Read more here.

Reference

Southwick K, Adams EH, Greenko J, et al. New York State 2016-2018: progression from Candida auris colonization to bloodstream infection. Presented at: 2018 ID Week; October 3-7, 2018; San Francisco, California. Abstract 2039.

Related Articles
CROI 2020 to be Held Virtually Due to COVID-19 Outbreak
Jun 02, 2020
FDA Approves New Antibacterial Drug for Serious Lung Disease Under Novel Pathway
Mar 16, 2020
No Benefit Associated with Tetanus, Diphtheria Booster in Adults
Mar 05, 2020